Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 18,148 shares at $29.11 ($528K) on 2024-12-16, disclosed to the SEC on 2024-12-18.
Scheduled sale ($528k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.11 | 9,074 | $264K | 50.0% |
| 2 | $29.11 | 9,074 | $264K | 50.0% |
| Total | $29.11 avg | 18,148 | $528K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |